The broadening spectrum of mitochondrial disease: Shifts in the diagnostic paradigm  by Liang, Christina et al.
Biochimica et Biophysica Acta 1840 (2014) 1360–1367
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbagenReviewThe broadening spectrum of mitochondrial disease:
Shifts in the diagnostic paradigm ☆☆Christina Liang a, Kate Ahmad a, Carolyn M. Sue a,b,⁎
a Department of Neurology, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia
b Department of Neurogenetics, Kolling Institute of Medical Research, Royal North Shore Hospital and the University of Sydney, St. Leonards, New South Wales 2065, Australia☆☆ This article is part of a Special Issue entitled Frontier
⁎ Corresponding author at: Departments of Neurology
Shore Hospital and Kolling Institute of Medical Resea
Leonard's, NSW 2065, Australia. Tel.: +61 2 9463 1828; f
E-mail address: carolyn.sue@sydney.edu.au (C.M. Sue
0304-4165 © 2013 The Authors. Published by Elsevier B.V
http://dx.doi.org/10.1016/j.bbagen.2013.10.040a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 July 2013
Received in revised form 21 October 2013
Accepted 26 October 2013
Available online 13 November 2013
Keywords:
Mitochondrial disease
FGF21
Next-generation-sequencing
Background: The diagnosis of mitochondrial disease requires a complex synthesis of clinical, biochemical, histo-
logical, and genetic investigations. An expanding number ofmitochondrial diseases are being recognized, despite
their phenotypic diversity, largely due to improvements in methods to detect mutations in affected individuals
and the discovery of genes contributing tomitochondrial function. Improved understanding of the investigation-
al pitfalls and the development of new laboratory methodologies that lead to a molecular diagnosis have neces-
sitated the ﬁeld to rapidly adopt changes to its diagnostic approach.
Scope of review:We review the clinical, investigational and genetic challenges that have resulted in shifts to the
way we deﬁne and diagnose mitochondrial disease. Incorporation of changes, including the use of ﬁbroblast
growth factor 21 (FGF-21) and next generation sequencing techniques,may allow affected patients access to ear-
lier molecular diagnosis and management.
Major conclusions: There have been important shifts in the diagnostic paradigm for mitochondrial disease. Diag-
nosis of mitochondrial disease is no longer reliant onmuscle biopsy alone, but should include clinical assessment
accompanied by the use of serological biomarkers and genetic analysis. Because affected patients will be deﬁned
on a molecular basis, oligosymptomatic mutation carriers should be included in the spectrum of mitochondrial
disease. Use of new techniques such as the measurement of serum FGF-21 levels and next-generation-
sequencing protocols should simplify the diagnosis of mitochondrial disease.
General signiﬁcance: Improvements in the diagnostic pathway for mitochondrial disease will result in earlier,
cheaper and more accurate methods to identify patients with mitochondrial disease. This article is part of a Spe-
cial Issue entitled Frontiers of Mitochondrial Research.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Mitochondrial disease represents a group of metabolic disorders
with the common link of impaired mitochondrial function. Because
themitochondria play a crucial role in providing themain energy source
for the cell, body tissues that require the most energy are most com-
monly affected. Organs that are most frequently affected include the
brain, muscle, heart, retina and cochlea. The clinical presentation of mi-
tochondrial disorders can be extremely variable, although for many dif-
ferent tissues, there are speciﬁc ‘red-ﬂags’ that can provide clues to thes of Mitochondrial Research.
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. Open access under CC BY-NC-ND licendiagnosis of a mitochondrial disease. The age of onset of mitochondrial
disease is also highly variable, with some disorders presenting from
very early in the neonatal period and others not becoming manifest
until late in adulthood. Further complexity arises as a result of the
dual genomic expression of mitochondrial proteins from both nuclear
(nDNA) and mitochondrial DNA (mtDNA).
Since Luft's ﬁrst description of a rare syndrome in a young woman
who had evidence of mitochondrial dysfunction and symptoms of
hypermetabolism in the absence of thyroid disease [1], the number of
mitochondrial diseases has expanded to include over 100 distinct dis-
ease entities. With the advent of molecular genetics, the discovery
of improved biomarkers and new sequencing platforms to perform
targeted exome and whole genome sequencing, traditional approaches
to diagnosing mitochondrial disease are now being challenged. Wewill
review these conventional approaches, focus on the pitfalls of these
established techniques and draw attention to the new advances that
may improve the diagnostic pathway for affected patients. Application
of thesemethodswill represent shifts in thediagnostic paradigm formi-
tochondrial disease and may lead to improved diagnostic accuracy and
clinical management of patients.se.
1361C. Liang et al. / Biochimica et Biophysica Acta 1840 (2014) 1360–13672. Diagnosis of mitochondrial disease based on clinical features
2.1. Clinical features suggestive of mitochondrial disease
The diagnosis of mitochondrial disease is initially raised by speciﬁc
clinical manifestations that cluster with additional features such as lac-
tic acidosis or other evidence of impaired mitochondrial respiratory
chain function (see Fig. 1). Affected patients may present anytime
from birth to late adulthood and the clinical manifestations can vary de-
pending on the age of symptom onset. Notably, the severity of disease
may range from life-threatening to asymptomatic or oligosymptomatic
mutation carriers. Why some individuals develop a syndromic illness
and others fail to develop the full spectrum of disease is currently un-
known. Furthermore, factors that inﬂuence the evolution of relatively
mild disease in oligosymptomatic subjects to one with a more severe
disease course remain unclear.
Children often present with different clinical features when com-
pared to adults. Common clinical presentations of children include fail-
ure to thrive, motor regression, metabolic encephalopathy, seizures,
ptosis, external ophthalmoplegia and cardiomyopathy. Most frequent
clinical manifestations associated with adult mitochondrial disease in-
clude exercise intolerance, sensorineural hearing loss, ophthalmological
abnormalities (retinal pigmentary changes, ptosis, progressive external
ophthalmoplegia, optic atrophy), muscle weakness (proximal limb
weakness, dysphagia, dysarthria), central nervous system involvement
(focal neurological deﬁcits, migraine, seizures), cardiac manifestations
(cardiac arrhythmia, hypertrophic cardiomyopathy, conduction block),
gastrointestinal system abnormalities (pseudo-obstruction, constipa-
tion) and endocrine abnormalities (diabetes, short stature and rarely
hypoparathyroidism and hypogonadism). Some of thesemanifestations
carry a short differential diagnosis, but many are non-speciﬁc and com-
mon. It is then important to consider the abnormality in more detail,
that is, the hearing loss of mitochondrial disorders maybe asymmetricalSeizures:
Acute de novo onset status epilepticus 
Focal/ multi-focal myoclonus
Triggered by physiological decompensation 
Well-controlled inter-ictal periods
Exacerbated by sodium valproate
Eye manifestations:
Ptosis
Asymmetric onset
Frontalis overactivity with preserved orbicularis oculi strength
Slow progression, little diurnal variation
Progressive external ophthalmoplegia 
Retinal pigmentary changes 
Perimacular in distribution
vision not affected in general 
Diabetes:
Occur in the young and non-overweight
Less liable to diabetic retinopathy/ neuropathy
Myopathy:
Symmetrical proximal involvement 
Can have significant myalgia
Fig. 1. Clinical features suggestiveand can partially recover [2]; mitochondrial disease associated diabetes
is seen in younger, non-obese patients [3,4], and may only manifest
during times of physiological stress. Fig. 1 summarizes these clinical fea-
tures that are more speciﬁc for mitochondrial disease.
Clinical features may also cluster into recognizable syndromes.
There are several of these that are common enough to warrant clinician
awareness. The MELAS syndrome (mitochondrial encephalopathy,
lactic acidosis and stroke-like episodes) is most commonly caused
by a tRNA point mutation, the m.3243ANG mutation [5–7] but
other mtDNA mutations may cause the same phenotype including
m.3271TNC, m.3291TNC, or m.13513GNA. MERRF syndrome (myoclonic
epilepsy with ragged red ﬁbers) is also associated with a tRNA point
mutation, usually m.8344ANG, but m.8356TNC and m.8363GNA are
also causally related to this syndrome. A single deletion in mtDNA
may result in Kearns-Sayre syndrome, chronic progressive external
ophthalmoplegia (CPEO) or Pearson's syndrome. Leber's hereditary
optic neuropathy (LHON) is commonly associated with one of
three point mutations, m.11778GNA, m.3460GNA, and m.14484TNC.
Other recognizable syndromes of mitochondrial disease include NARP
(neuropathy, ataxia and retinitis pigmentosa), Leigh's disease and
MNGIE (mitochondrial neurogastrointestinal encephalomyopathy).
Table 1 details classical mitochondrial disease syndromes [7–11].
In addition to suggestive clinical features, the family history may
provide important information when a diagnosis of mitochondrial dis-
ease is being considered. Maternal inheritance is highly suggestive of a
defect in mtDNA. This is because at conception, all surviving mtDNA is
derived from the mother's ovum. This leads to the situation where a
pathogenicmutation in an affectedmother is transmitted to all her chil-
dren, but only her daughters will transmit the mutation to their proge-
ny. Hence, a disease that is expressed in both sexes, but not transmitted
from a male to his progeny is highly suggestive of a mtDNA defect.
Identical pathogenic mutations may cause disease at different
ages and cause different clinical syndromes [12]. Why this occurs isHearing loss:
Asymmetric, young-onset sensorineural hearing loss
History of partial recovery at some point
CNS involvement:
Young-onset focal neurological deficit, typically associated with a clinical 
prodrome, focal seizures/ myoclonus, status epilepticus
Grey-matter affected that does not follow vascular territory and potentially 
reversible
Basal ganglia calcification
Elevated CSF lactate
Gastrointestinal dysmotility: 
Severe constipation, can fluctuate with diarrhoea
Intermittent presentations with pseudo-obstruction
Neuropathy:
Subclinical involvement
Axonal or demyelinating or a sensory ganglionopathy 
of a mitochondrial disorder.
Table 1
Summary of syndromic clinical phenotypes of mitochondrial disease (modiﬁed from C. Liang, C. M. Sue, How to Treat: Mitochondrial disease, Australian Doctor Mar 25 (2011) 27–34).
Clinical phenotype Type of mutation typically associated with phenotype Common clinical features
MELAS syndrome [4] tRNA point mutations: m.3243ANG, m.3271TNC,
m. 3291TNC, m.13513GNA
Cardinal— stroke-like episodes with clinical prodrome, areas of high signal on
T2 weighted MRI that do not conform to vascular territories, lactic acidosis.
Other — hearing loss, diabetes mellitus, gastrointestinal, short stature.
MERRF syndrome [5] tRNA Point mutation: m.8344ANG, m. 8356TNC m.8363GNA Cardinal — weakness, myoclonus and epilepsy. Other — multiple lipomata in
‘collar’ distribution, hearing loss, dementia, neuropathy.
Kearns-Sayre syndrome/CPEO [6] Single deletion
Deletion/duplications (rare)
Ptosis, PEO, retinal pigmentary abnormalities, short stature, ataxia, cardiac
conduction abnormalities, proximal and bulbar weakness.
Leigh's disease [7] Point mutation in protein subunit Bilateral characteristic basal ganglia lesions, psychomotor retardation,
seizures, movement disorders, lactic acidosis.
Leber's hereditary optic
neuropathy [8]
Point mutation in protein subunit: m.11778GNA,
m.3460GNA, m.14484TNC
Rapidly progressive, usually sequential visual loss commonly in young males.
Characteristic fundal appearance.
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tribution of mtDNA mutations (that is, heteroplasmy, where mutant
mtDNA coexists with the wild type mtDNA in varying proportions;
threshold effects of the tissue at the time; environmental stressors and
the underlying nuclear genetic backgrounds.)
As nuclear DNA mutations may also cause mitochondrial disease
(nuclear genes are required to encode the majority of respiratory
chain subunits, for the assembly of the respiratory chain, inter-
genomic signaling, protein import and mitochondrial motility), there
may be a family history more suggestive of an autosomal dominant or
recessive disease. In adults, mutations in POLG, thymidine phosphory-
lase, ANT1 and TWINKLE are the commonest nuclear encoded mito-
chondrial disease causing genes.
2.2. Problems with clinical diagnosis
Although mitochondrial disease may be suspected clinically, the di-
agnosis often remains uncertain until investigations such as amuscle bi-
opsy or genetic tests conﬁrm an abnormality. There have been several
published diagnostic criteria which purport to assist in the recognition
and diagnosis of mitochondrial disorders. Walker et al. were the ﬁrst
to propose a set of major and minor criteria for the identiﬁcation of mi-
tochondrial disorders [13]. The Walker criteria were then modiﬁed by
Bernier et al. in 2002 and are now known as ‘the modiﬁed Walker
criteria’ [14] to better serve the pediatric presentations. Other attempts
to deﬁne diagnostic criteria include the Nijmegen Center for Mitochon-
drial Disorders scoring system [15] and the Mitochondrial Disease
Criteria [16]. All of these diagnostic systems are based on a combination
of clinical, laboratory, pathologic, biochemical, and genetic ﬁndings.
They are useful for deﬁning patients in research studies, but may not al-
ways be practical in day to day practice, where expensive investigations
may be limited andwhere patientsmay be better served by a conclusive
answer rather than a more ambiguous likelihood rating (e.g. ‘possible’
or ‘probable’ disease). Finally, poor phenotype–genotype correlations
and the presence of oligosymptomatic and asymptomatic mutation car-
riers that obscure a positive family history can all affect the accuracy of
clinical diagnosis in mitochondrial disease.
2.2.1. Phenotypic variability
Even within families carrying the same mutation, there is extreme
phenotypic variability [12]. The m.3243ANG mutation, one of the most
common mtDNA point mutations, provides a good example of this.
The best known and severest clinical phenotype associated with the
m.3243ANG point mutation is the MELAS syndrome. Potentially,
this syndrome can be lethal in childhood. In addition to the MELAS
syndrome, there are patients with milder phenotypes such as MIDD
(maternally inherited diabetes and deafness), CPEO, non-syndromic
symptom clusters, oligo/asymptomatic forms and a variety of other oc-
casionally described phenotypes. We have found that only 25% of
m.3243ANG mutation carriers suffer a stroke-like episode [17] and a
UK study of 129 patients with the m.3243ANG mutation found thatonly about half of the patients had symptomswhich beﬁt a classical syn-
drome. 10% had features consistent with MELAS; 30% had MIDD, 6% had
a MELAS/MIDD overlap, 7% had a CPEO overlap syndrome, 28% had a
wide range of symptom clusters that did not conform to any syndromic
diagnosis and 9% were asymptomatic [18]. It should be noted that as
these patients were drawn from a mitochondrial database, it is possible
that symptomatic disease may have been over-represented.
Another recent study investigating the clinical features of theMERRF
syndrome associated mutation, m.8344ANG reported that 4 of the
39 patients within their database were asymptomatic and 4 were
oligosymptomatic (isolated ptosis, hypogonadism and lipomatosis). The
more severely affected patients had an array of both central nervous sys-
tem and neuromuscular signs, in addition to other organ involvement in
the form of diabetes, heart disease and multiple lipomata. The mean age
of death was 37.5 years (n = 4) [19]. This again demonstrates the ex-
treme phenotypic variability from asymptomatic to lethal multi-organ
disease. This group also failed to ﬁnd correlation between muscle muta-
tion load and myopathic symptoms, and between the level of hetero-
plasmy and clinical severity or age of onset. There appeared to be few
clues as to which patients were at risk of developing severe disease.
As there is extreme variability even within families, having an oligo/
asymptomatic phenotype does not accurately predict the risk for the
offspring [20]. Indeed, it is not uncommon for the minimally affected
mother to be diagnosed after the assessment of amore severely affected
child [21]. Asymptomatic at-risk family members cannot rely on a pau-
city of clinical symptoms and signs to determine theirmutation status. It
then becomes potentially important to pursue a genetic diagnosis even
in patients with very mild disease.
Another problem with the classiﬁcation of asymptomatic or
oligosymptomatic mutation carriers is that the phenotype of individual
patients may change throughout life. Although an affected patient is
born with the genetic defect, it is very difﬁcult to pinpoint when mito-
chondrial disease ‘starts’. Patients may be well during early life and
only develop symptoms as they age. Thus, a mutation carrier has the po-
tential to develop symptoms anywhere along the full spectrum of mito-
chondrial disease. These patients carry a lifelong, relatively unpredictable
risk of developing symptoms, and their offsprings are potentially at risk
of severe disease (depending on speciﬁc genetic defect and mode of
transmission). A Finnish study examined 33 adult patients with the
m.3243ANG mutation. These patients were followed for 3 years and
the progression of their symptoms assessed. Seven of the patients died
during the follow-up period. Of the remaining patients, it was noted
that sensorineural hearing loss progressed, echocardiographic changes
progressed considerably, EEG ﬁndings changed and modiﬁed Rankin
score became worse [22]. It is clear that even with this relatively short
follow-up, an individual's phenotype and severity may change signiﬁ-
cantly over a lifetime.
2.2.2. Genotypic variability
Recognized mitochondrial disease phenotypes may be the result of
different genotypes. A single syndromic phenotype may be the result
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tations. TheMELAS phenotype is caused by them.3243ANG pointmuta-
tion in 80% of cases, but a similar phenotype is seen with m.3271TNC,
m.3291TNC, or m.13513GNA mutations. Other MELAS causing mtDNA
point mutations are increasingly reported in the medical literature.
The combination of stroke-like episodes and lactic acidosis may also
be seen as part of other mitochondrial syndromes. What may initially
appear as a MELAS phenotype clinically may evolve into something
different. Stroke-like episodes have been reported in Kearns-Sayre syn-
drome, Saguenay-Lac cytochrome oxidase deﬁciency and Leigh syn-
drome [23], further complicating the potential genotypic diagnosis of
a patient who phenotypically has MELAS. A MELAS-like phenotype
may also be the result of mutations in the POLG1 gene. A recent litera-
ture review identiﬁed 22 reported patients with stroke-like episodes
as a consequence of POLG1 mutations, some of whom were initially
misdiagnosed as mtDNA mutation related MELAS [24]. Differentiating
between mtDNA and nDNA mutations is of particular importance
given the differing mode of inheritance and implications for family
members.
CPEO, using the term as a syndromic diagnosis, may be the result of
mutations inmtDNA or nDNA andmay be sporadic or followmitochon-
drial or Mendelian inheritance patterns. Assigning inheritance pattern
based on clinical information reduces the genotypic variability, but
does not eliminate it, and this information is not always available or ac-
curate. Sporadic CPEO is usually the result of a single large scale rear-
rangement of mtDNA. Maternally inherited CPEO is most commonly
associated with the m.3243ANG mutation, but seventeen point muta-
tions in six of the 22 mitochondrial tRNA genes have been identiﬁed
as causing a CPEO phenotype. CPEO may also be inherited as a result
of nDNA mutations in either an autosomal dominant or recessive pat-
tern. These mutations usually cause multiple different large scale rear-
rangements of mitochondrial DNA. Six genes are associated with
CPEO: ANT1, TYMP, Twinkle, POLG1, POLG2 and OPA1 [25]. Given this
very large genotypic variability, the clinical examination and family his-
torymust be used to narrow down the possibilities, and guide the order
of investigation. Most mitochondrial syndromes carry a genotypic dif-
ferential and it is only the genotype that can accurately predict the
mode of genetic transmission.
2.2.3. Oligosymptomatic and asymptomatic mutation carriers
Finally, a positive family history may be overlooked due to mild dis-
ease, variability in clinical manifestations or because many relatives
may be asymptomatic carriers. Of note, in the m.8344ANG cohort men-
tioned above, 17 of 39 patients had no relatives with molecularly con-
ﬁrmed disease, and only 5 of these 17 had a maternal family history
indicative of mitochondrial disease [19].
While only population screening will identify all asymptomatic car-
riers, genetic screening for asymptomatic at-risk family members may
be more appropriate and of greater yield. Asymptomatic carriers may
become symptomatic later in life and thus beneﬁt from screening inves-
tigations, knowledge and avoidance of life-style factors which may ex-
acerbate mitochondrial disease, and genetic counseling, should they
wish to have children.
3. Diagnostic investigations for mitochondrial disease
Unless a classical mitochondrial disease phenotype is obvious, ac-
cording to the currently proposed diagnostic criteria [13,14], steps to ar-
rive at a more deﬁnitive diagnosis after clinically assessing a patient
require identiﬁcation of either indicative ﬁndings on a muscle biopsy,
or the detection of a known pathogenic mutation for mitochondrial dis-
ease. Laboratory evidence suggesting abnormal oxidative metabolism,
or abnormal respiratory chain enzymatic activities, may add to the
strength of the diagnosis, but these often have poor sensitivity, and
the methods used are not consistent between different laboratories
[15]. Auxiliary investigations, such as serum lactate and pyruvate levels,imaging studies, and neurophysiological studies may similarly help to
deﬁne the patient's disease syndrome, but are not deﬁnitive.
3.1. Diagnosis by muscle biopsy
Muscle biopsies are often necessary to better deﬁne the diagnosis for
patients with suggestive symptoms who do not ﬁt into a recognized
clinical syndrome, and in whom initial common mutation screening is
negative. Muscle samples may be used for morphological, biochemical
and genetic analyses. When the muscle biopsy is taken, it is important
that it is divided and stored differently for the various investigational
processes. Portions of muscle should be frozen in liquid nitrogen cooled
isopentane for morphological and histochemistrical studies, but freshly
frozen without isopentane for biochemical studies. Other portions
should be ﬁxed in parafﬁn for histological examination or stored in glu-
taraldehyde for electron microscopy as necessary [26]. Mitochondrial
genetic analysis for mtDNA mutations, including mtDNA rearrange-
ments, deletion and depletion can be best identiﬁed using frozen (not
ﬁxed) muscle tissue.
Speciﬁc tomitochondrial disease, histological evaluation traditional-
ly includes preparation of muscle sections with the modiﬁed Gomori
trichrome stain, which identiﬁes the historical “gold-standard” patho-
logical hallmark referred to as the “ragged red ﬁber”. Ragged red ﬁbers
(RRFs) are myoﬁbrils with excessive proliferation of mitochondria that
appear red from the sphingomyelin content in the mitochondrial mem-
brane [26]. Identiﬁcation of more than 2% RRFs in a muscle biopsy sam-
ple qualiﬁes the patient for a major diagnostic Walker criterion,
whereas 1–2% RRFs in a muscle sample from a patient, 30–50 years of
age (Fig. 2), or any amount found in those b30 years of age, qualiﬁes
the patient for a minor diagnostic Walker criterion [13,14].
Similarly, muscle sections can be stained with cytochrome c oxidase
(COX) and succinate dehydrogenase (SDH) stains. The presence ofmore
than 2% COX-negative ﬁbers in patients b50 years of age, or N5% in
those over 50 years of age constitute a major diagnostic Walker criteri-
on [13,14].
Demonstration of the ultrastructural changes of mitochondrial my-
opathy on electronmicroscopy complements lightmicroscopy ﬁndings.
The typical changes include: an excessive proliferation of mitochondria
with increased number of abnormally shaped and enlarged mitochon-
dria, abnormal architecture of the cristae in the mitochondria, and the
identiﬁcation of small intra-mitochondrial electron dense spherical
granules or globoid inclusions, and paracrystalline inclusions (which
are compressed crystallized cristae) [26,27]. Examination on electron
microscopy can be more sensitive than histological ﬁndings.
3.2. Problems with diagnosis by muscle biopsy
Muscle biopsy is an invasive procedure that may require a general
anesthetic, presenting an additional risk to the patient. There are issues
with specimen handling and transport, particularly if the muscle is ob-
tained froma site remote to the diagnostic laboratory. Biochemical stud-
ies need to be performed usingmuscle samples that are not frozen with
isopentane; while electron microscopy requires a muscle biopsy pre-
served in glutaraldehyde to avoid artifacts. Such speciﬁc sample testing
is best achieved when an institution has an established protocol for
preparation, delivery and analysis of the muscle sample. Access to cen-
ters that have the appropriate level of expertise to perform biochemical
and electronmicroscopic examination of muscle also represents further
complexity to the diagnostic pathway, in addition to the further ex-
pense that these investigations and protocols attract.
Muscle biopsy resultsmay have high false positive and false negative
rates. In order to qualify for the major diagnostic criterion, the patients'
biopsy needs to have a deﬁned percentage of RRF or COX-negative ﬁ-
bers. This can make a deﬁnitive diagnosis difﬁcult, as it is not uncom-
mon for patients with mitochondrial diseases to have no RRF and/or a
lower percentage of COX-negative ﬁber identiﬁed on their muscle
A B C
Fig. 2. A) Hemotoxylin & eosin stain: showing basophilic change to a myoﬁber, and a number of others with a basophilic rim. B)Modiﬁed Gomori trichrome stain: A ragged red ﬁber that
stains darker is noted, and several others with a hint of red subsarcolemmal rim are seen. C) Cytochrome-c oxidase (COX) combined with succinate dehydrogenase (SDH) stain: the COX
negative ﬁbers (n = 4) clearly stand out after counter-staining with SDH. (Photos courtesy of Dr Janice Brewer)
1364 C. Liang et al. / Biochimica et Biophysica Acta 1840 (2014) 1360–1367biopsies.Moreover, the ﬁnding of RRF is dependent on age. RRFs are not
generally found in biopsies of children b5 years [26], and may not be
found in young adults with mitochondrial disease. Thus, there is poor
sensitivity for younger patients. On the other hand, in one study, 85%
of muscle specimens from older subjects showed N1 RRF per low
power ﬁeld [28]. RRFs can also be found in other conditions such as in-
ﬂammatory myopathies such as inclusion body myositis [28], heredi-
tary myopathies such as desminopathy, toxic myopathies (including
in the use of statin and zidovudine) and metabolic myopathy with
acidmaltase deﬁciency, the latter condition in which the ultrastructural
ﬁnding of paracrystalline inclusions in mitochondria can also be found
[26].
Thus, muscle biopsy ﬁndings are not deﬁnitive in its diagnosis and
need to be put into the context of the patient's clinical presentation,
and the rest of other auxiliary investigations.
4. Diagnosis by genetics
4.1. The traditional approach to genetic diagnosis
Since the ﬁrst report of mutations in mitochondrial DNA being asso-
ciated with human disease in 1988, the ﬁnding of an established patho-
genic mutation in a patient with clinical features of mitochondrial
disease has proven to be the most deﬁnitive way to diagnose a patient
with mitochondrial disease. Mitochondrial disease can be caused by
mutations in either themitochondrial or the nuclear genome. Hundreds
of pathogenic mtDNA mutations have been reported in the literature,
such that a database of reported mtDNA mutations can be found at
www.mitomap.org. Mutations in the nuclear genome (nDNA) have
also been reported to cause mitochondrial disease. Nuclear gene muta-
tions associated with a primary mitochondrial disorder can cause de-
fects in the respiratory chain subunits and ancillary proteins, impair
intergenomic communication inﬂuencing mtDNA maintenance or ex-
pression, impair biosynthetic enzymes for lipids or cofactors, altermito-
chondrial trafﬁcking or biogenesis, or lead to defective apoptosis.
Affected adults aremore likely tohavemutations inmtDNA,whereas af-
fected children may have mutations in either genome.
Largely because of the expense and limited availability, genetic test-
ing has traditionally been performed in a step-wise and selective man-
ner, based on the patient's clinical phenotype and family history. For
example, a patient with CPEO but no family history is suggestive of a
sporadic mtDNA deletion whereas, if the same patient had amaternally
transmitted pattern of inheritance, then consideration to common caus-
ative mutations in mtDNA (e.g. m.3243ANG) may be pursued. In con-
trast, a patient with CPEO and a Mendelian pattern of inheritance (in
either an autosomal dominant or autosomal recessive manner) would
justify sequencing of nuclear genes that are known to cause this pheno-
type (e.g. POLG, ANT1, TWINKLE) [29]. The results of other auxiliary tests
can also direct targeted genetic testing. For example, if serumor urinarythymidine is elevated in a patient with ophthalmoplegia and gastroin-
testinal dysmotility, then the TYMP genemay be tested to conﬁrmmito-
chondrial neurogastrointestinal encephalopathy (MNGIE) or; if mtDNA
depletion is identiﬁed on Southern-blot, and the patient has elevated
creatinine kinase, then testing for RRM2B or TK2 genes might be
considered.
4.2. Problem with diagnosis by genetics
The main problem with diagnosing mitochondrial disease with ge-
netic testing is the vast number of causative genes that have been asso-
ciated with mitochondrial disease. First of all, the number of candidate
genes for testing amongst an ever-growing list of potential causative
genes [30] can be difﬁcult to rationalize, particularly given the variabil-
ity in phenotype–genotype correlations.
For mitochondrial diseases, genetic testing needs to be performed in
the correct clinical context and on the appropriately selected tissue.
With regard to mtDNA mutations, selection of an appropriate tissue is
important to optimize the chance of identifying a disease-causingmuta-
tion andmay differ to that required for the identiﬁcation ofmutations in
nuclear DNA. While some mtDNA mutations are homoplasmic and af-
fect a single organ (such as for Leber's hereditary optic neuropathy),
the majority of mitochondrial disorders caused by mutant mtDNA are
heteroplasmic and may be selected out of various tissues (such as
blood) over time [31–34], while being retained in others (such as mus-
cles, hair follicles, and urine epithelial cells) [29]. For example, muscle is
the tissue of choice for the identiﬁcation of mtDNA rearrangements, de-
letions or depletion using Southern blot or quantitative real time PCR
methodologies. In Kearns-Sayre syndrome (KSS) and chronic progres-
sive external ophthalmoplegia (CPEO), mtDNA deletions are best
detected in muscles, whereas in Pearson's syndrome, the mtDNA dele-
tions may be found only in white blood cells [29].
4.3. Deﬁning if mutational-carriers have the disease
Genetic testing of familieswithmitochondrial disease (e.g. inMELAS
and MERRF) has revealed that the majority of family members are
oligosymptomatic, but some have more severe disease, with the full
clinical syndrome. Inclusion of oligosymptomatic mutation carriers
under the umbrella of mitochondrial disease is warranted, given that
these individuals may also develop a similar phenotype to the index
case at a later point in time. In this sense, it is difﬁcult to deﬁne when
mitochondrial disease begins clinically. Probands often have clinical
manifestations of mitochondrial disease heralding an acute presenta-
tion or the full syndromic illness. Factors that lead to the development
of severe diseases are still largely unknown. Oligosymptomatic muta-
tion carriers still require treatment and management of their clinical
symptoms, and may transmit the pathogenic genetic mutation that
can cause syndromic mitochondrial disease to their offspring.
Current diagnostic 
pathway
Clinical assessment
Histological and biochemical muscle 
biopsy analysis
Mitochondrial and nuclear DNA 
mutations screening analysis
25-50% diagnosis
Proposed diagnostic 
pathway
Clinical assessment
Serum FGF-21 levels
Long range PCR & Next generation 
sequencing protocols of mtDNA or 
nDNA whole-exome
+/-Histological and biochemical 
muscle biopsy analysis
?70-80% diagnosis
Fig. 3. Proposed changes to the diagnostic pathway for mitochondrial disease.
Modiﬁed from C. M. Sue, The Mitochondrial Disease Report: Progress Towards Overcom-
ing Life's Energy Crisis (2013).
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Early epidemiologic studies estimated a minimum population prev-
alence of mitochondrial disease as between 9.2 and 16.5 in 100,000
[35–37]. These early studies aimed to determine the minimum birth
prevalence of mitochondrial disease and may have underestimated
the true prevalence of these disorders as they relied on already diag-
nosed case referrals and census data to calculate their estimates and
did not account for the fact that many patients with mitochondrial dis-
ease in the community remain undiagnosed or misdiagnosed [38].
Another example is illustrated by prevalence studies onMELAS syn-
drome (mitochondrial encephalopathy, lactic acidosis and stroke-like
episodes), ﬁrst described 1984 [7], whichwasmost commonly associat-
ed with the m.3243ANG mutation in 1990 [6,39]. A Finnish study origi-
nally calculated a disease prevalence of 10.2/100 000, and a minimal
m.3243ANGmutational prevalence of over 16.3/100,000 [40]. Themuta-
tional prevalence was subsequently revised to be much higher at 236/
100,000 [41], amongst an Australian community-based cohort aged
50 years or older, indicating that undiagnosed, oligosymptomatic indi-
viduals are common in the population at large.
We continued our ﬁrst series of community-based study to deter-
mine the prevalence of mitochondrial disease in the Australian popula-
tion and found that 1 in 250 Australians had one of two common
mtDNA mutations [41–43] and were thus at-risk of developing or
had undiagnosed mitochondrial disease. Other prevalence studies
have now also conﬁrmed our ﬁndings and thus it has been established
that the frequency of mtDNA mutations amongst ‘healthy’ or
oligosymptomatic subjects is between 1 in 200–250 persons [43,44]. It
is likely, however, that these studies, which are limited to testing only
the common mutations, are still underestimating the true prevalence
of all types of mitochondrial disease.
Thus, the problem arises as to whom we should deﬁne as having
a mitochondrial disease. If we consider that only patients who
manifest classical phenotypes as being affected, large numbers of
oligosymptomatic affected individuals would be excluded and remain
at risk of developing more severe disease. Lifestyle changes such as ex-
ercise programs, and supportive treatments can be helpful to minimize
disease progression and ideally, diseasemonitoring should be offered to
mutational carriers tominimize the risk of the disease in future [45]. If it
is deﬁned as all individuals carrying a known pathological mutation,
then, the potential population needing medical attention could be
very large. We propose that those individuals with known pathogenic
mutations and at least one clinical manifestation be considered as hav-
ing a mitochondrial disease, while unaffectedmutations carriers should
be classiﬁed as ‘at-risk’. This highlights the need to better stratify the
risks of these individuals in developing disease or future morbidity, in
order to better assess the cost-effectiveness of screening and monitor-
ing for the mutational carriers of each type of mitochondrial disease.
6. New advances in the diagnosis of mitochondrial disease
6.1. Next generation sequencing protocols
Because of the rapidly increasing number of mutated genes that
are associated with mitochondrial disease, and the poor genotypic–
phenotypic correlation in these patients, sequential sequencing of
possible disease causingmitochondrial and nuclear genes can be prohib-
itively expensive and extensive. The utility of targeted exome sequenc-
ing and whole genome sequencing is currently being evaluated. New
methods using massively parallel sequencing allows rapid, accurate se-
quencing of large amounts of DNA at lower costs [46]. First attempts to
identify pathogenic mutations with next generation sequencing (NGS)
protocols in a cohort of patients with severe infantile cases of mitochon-
drial disease deﬁnedon strict biochemical grounds andproven respirato-
ry chain enzyme deﬁciency found that 26% of patients were identiﬁed as
having pathogenic mutations causative of their mitochondrial disease[47]. Interestingly, only one child had an mtDNA mutation (deletion)
and the other disease causing mutations were within nuclear encoded
genes. Another study showed that their NGS protocolwas able to reliably
identify 17 of the 18 patients with known mtDNA mutations and all of
the known nDNA mutations, demonstrating the diagnostic accuracy of
this technique and underpinning the importance of correct tissue sam-
pling, given that the mtDNA mutation ‘missed’ was only present at a
low level of heteroplasmy (3%) in the tissue studied [48]. This latter
study also demonstrated that when diagnostic criteria were made on
less stringent clinical grounds, only 6%of cryptogenic patientswere iden-
tiﬁed to have a disease causing pathogenic mutation. In both studies, ad-
ditional patients were identiﬁed with sequence variants for which
further studies were required to determine pathogenicity, emphasizing
the need for further functional assessment of sequence variants identi-
ﬁed by NGS protocols. NGS protocols and other genetic analyses that in-
clude long-range PCR analysis to detect multiple mtDNA deletions or
depletion may also be helpful to identify the broad range of genetic de-
fects and mutations associated with mitochondrial disease.
6.2. Fibroblast growth factor-21
Given that patient selection on clinical grounds may not be the best
way to stratify DNA samples for NGS, we have proposed that the use of a
biomarker such as serumof Fibroblast Growth Factor 21 (FGF-21) levels
may be helpful in aiding the diagnostic pathway for patients with mito-
chondrial disease [49]. Serum levels of FGF-21were ﬁrst shown to be el-
evated in patients with mitochondrial disease by Suomalainen and
colleagues, particularly if there was muscle involvement [50]. FGF-21
is a metabolic hormone and master regulator of energy balance and is
particularly involved in lipid mobilization and the starvation response
[51,52].Mouse studies have shown that induction of FGF-21 is speciﬁcal-
ly due to respiratory chain deﬁciency [53]. We and others have found
that serum FGF-21 levels display greater sensitivity than other classical
indicators, such as serum lactate, pyruvate and creatine kinase levels
and can distinguish mitochondrial disease from other neuromuscular
disease and control subjects [49,50]. FGF-21 may be elevated in both
mtDNAand nDNAencodedmitochondrial diseases [49] aswell as adults
and childrenwithmitochondrial disease [49,50].We propose to use this
marker as a screening tool for patients suspected of having mitochon-
drial disease, so that those with elevated FGF-21 levels, and thus more
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screening. However, FGF-21 levels may also be elevated in other condi-
tions, including obesity and fasting. Thus, the clinical application of this
biomarker needs to be further evaluated in largerwell-characterized co-
horts,with standardized protocols set up to ensure the clinical reliability
of this test. We hypothesize that the diagnostic pathway for patients
with mitochondrial disease may change as in Fig. 3.
7. Conclusions
The diagnosis of mitochondrial disease is complex and problematic.
Traditional approaches to diagnose this group of disorders rely on clin-
ical, auxiliary investigations and genetic analyses. There are problems
and pitfalls with each of these approaches. New sequencing techniques
such as next generation sequencing of targeted exomes have increased
the diagnostic yield of older techniques. The use of serological bio-
markers such as serum FGF-21 levels also offer promise to improve
the diagnosis of such disorders. We conclude that new methodological
advances in the genetic assessment of mitochondrial disease in combi-
nation with the discovery of new biomarkers such as serum FGF-21
levels will become established as a new diagnostic pathway for patients
withmitochondrial disease. Identiﬁcation of individualswith pathogen-
ic mutations associated with disease symptoms indicative of mitochon-
drial disease will conﬁrm that mitochondrial disease is no longer a rare
group of fatal infantile or childhood-onset disorders but rather a vast
group of disorders that can present at any age and potentially affect 1
in 200–250 people. PathogenicmtDNA and nDNA defects are associated
with a spectrum of clinical disease, inclusive of oligosymptomaticmuta-
tion carriers as well as recognized clinical syndromes. Muscle biopsy
will no longer remain as the gold standard to diagnose mitochondrial
disease as it will become ancillary to alternative diagnostic methods
such as new NGS techniques in concert with the use of new biomarkers
of mitochondrial disease. Improvements in the diagnostic pathway will
establish a shift in the diagnostic paradigm for patients with mitochon-
drial disease, constituting further progress in the ﬁeld of mitochondrial
medicine.
References
[1] R. Luft, D. Ikkos, G. Palmieri, L. Ernster, B. Afzelius, A case of severe hypermetabolism
of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory
control: a correlated clinical, biochemical, andmorphological study, J. Clin. Invest. 41
(1962) 1776–1804.
[2] C.M. Sue, L.J. Lipsett, D.S. Crimmins, C.S. Tsang, S.C. Boyages, C.M. Presgrave, W.P.
Gibson, E. Byrne, J.G. Morris, Cochlear origin of hearing loss in MELAS syndrome,
Ann. Neurol. 43 (1998) 350–359.
[3] S.S. Gebhart, J.M. Shoffner, D. Koontz, A. Kaufman, D. Wallace, Insulin resistance as-
sociated with maternally inherited diabetes and deafness, Metabolism 45 (1996)
526–531.
[4] M. Shigemoto, Y. Yoshimasa, Y. Yamamoto, T. Hayashi, J. Suga, G. Inoue, M. Okamoto,
H. Jingami, K. Tsuda, T. Yamamoto, T. Yagura, M. Oishi, S. Tsujii, H. Kuzuya, K. Nakao,
Clinical manifestations due to a point mutation of the mitochondrial tRNAleu(UUR)
gene in ﬁve families with diabetes mellitus, Intern. Med. 37 (1998) 265–272.
[5] Y. Goto, Clinical features of MELAS andmitochondrial DNAmutations, Muscle Nerve
Suppl. 3 (1995) S107–S112.
[6] Y. Goto, I. Nonaka, S. Horai, A mutation in the tRNA(Leu)(UUR) gene associatedwith
the MELAS subgroup of mitochondrial encephalomyopathies, Nature 348 (1990)
651–653.
[7] S.G. Pavlakis, P.C. Phillips, S. DiMauro, D.C. De Vivo, L.P. Rowland, Mitochondrial my-
opathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical
syndrome, Ann. Neurol. 16 (1984) 481–488.
[8] N. Fukuhara, S. Tokiguchi, K. Shirakawa, T. Tsubaki, Myoclonus epilepsy associated
with ragged-red ﬁbres (mitochondrial abnormalities): disease entity or a syn-
drome? Light-and electron-microscopic studies of two cases and review of litera-
ture, J. Neurol. Sci. 47 (1980) 117–133.
[9] T.P. Kearns, G.P. Sayre, Retinitis pigmentosa, external ophthalmophegia, and com-
plete heart block: unusual syndrome with histologic study in one of two cases,
AMA Arch. Ophthalmol. 60 (1958) 280–289.
[10] J. Finsterer, Leigh and Leigh-like syndrome in children and adults, Pediatr. Neurol. 39
(2008) 223–235.
[11] P.Y. Man, D.M. Turnbull, P.F. Chinnery, Leber hereditary optic neuropathy, J. Med.
Genet. 39 (2002) 162–169.
[12] D. Crimmins, J.G. Morris, G.L. Walker, C.M. Sue, E. Byrne, S. Stevens, B. Jean-Francis, C.
Yiannikas, R. Pamphlett, Mitochondrial encephalomyopathy: variable clinical ex-pression within a single kindred, J. Neurol. Neurosurg. Psychiatry 56 (1993)
900–905.
[13] U.A.Walker, S. Collins, E. Byrne, Respiratory chain encephalomyopathies: a diagnos-
tic classiﬁcation, Eur. Neurol. 36 (1996) 260–267.
[14] F.P. Bernier, A. Boneh, X. Dennett, C.W. Chow, M.A. Cleary, D.R. Thorburn, Diagnostic
criteria for respiratory chain disorders in adults and children, Neurology 59 (2002)
1406–1411.
[15] D.R. Thorburn, J. Smeitink, Diagnosis of mitochondrial disorders: clinical and bio-
chemical approach, J. Inherit. Metab. Dis. 24 (2001) 312–316.
[16] N.I. Wolf, J.A. Smeitink, Mitochondrial disorders: a proposal for consensus diagnostic
criteria in infants and children, Neurology 59 (2002) 1402–1405.
[17] C.M. Sue, D.S. Crimmins, Y.S. Soo, R. Pamphlett, C.M. Presgrave, N. Kotsimbos, M.J.
Jean-Francois, E. Byrne, J.G. Morris, Neuroradiological features of six kindreds with
MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis, J. Neurol.
Neurosurg. Psychiatry 65 (1998) 233–240.
[18] V. Nesbitt, R.D. Pitceathly, D.M. Turnbull, R.W. Taylor, M.G. Sweeney, E.E.
Mudanohwo, S. Rahman, M.G. Hanna, R. McFarland, The UK MRC Mitochondrial
Disease Patient Cohort study: clinical phenotypes associated with the m.3243ANG
mutation — implications for diagnosis and management, J. Neurol. Neurosurg.
Psychiatry 84 (2013) 936–938.
[19] M. Mancuso, D. Orsucci, C. Angelini, E. Bertini, V. Carelli, G.P. Comi, C. Minetti, M.
Moggio, T. Mongini, S. Servidei, P. Tonin, A. Toscano, G. Uziel, C. Bruno, E.
Caldarazzo Ienco, M. Filosto, C. Lamperti, D. Martinelli, I. Moroni, O. Musumeci, E.
Pegoraro, D. Ronchi, F.M. Santorelli, D. Sauchelli, M. Scarpelli, M. Sciacco, M.
Spinazzi, M.L. Valentino, L. Vercelli, M. Zeviani, G. Siciliano, Phenotypic heterogene-
ity of the 8344ANG mtDNA “MERRF” mutation, Neurology 80 (2013) 2049–2054.
[20] J.M. Vento, B. Pappa, Genetic counseling inmitochondrial disease, Neurotherapeutics
10 (2013) 243–250.
[21] Y.Y. Ma, T.F. Wu, Y.P. Liu, Q. Wang, X.Y. Li, J.Q. Song, X.Y. Shi, W.N. Zhang, M. Zhao,
L.Y. Hu, Y.L. Yang, L.P. Zou, Heterogeneity of six children and their mothers with mi-
tochondrial DNA 3243 ANG mutation, Mitochondrial DNA 24 (2013) 297–302.
[22] K.A. Majamaa-Voltti, S. Winqvist, A.M. Remes, U. Tolonen, J. Pyhtinen, S. Uimonen,
M. Karppa, M. Sorri, K. Peuhkurinen, K. Majamaa, A 3-year clinical follow-up of
adult patients with 3243ANG in mitochondrial DNA, Neurology 66 (2006)
1470–1475.
[23] J. Finsterer, Stroke and stroke-like episodes in muscle disease, Open Neurol. J. 6
(2012) 26–36.
[24] W. Brinjikji, J.W. Swanson, C. Zabel, P.J. Dyck, J.A. Tracy, R.H. Gavrilova, Stroke and
stroke-like symptoms in patients with mutations in the POLG1 gene, JIMD Rep. 1
(2011) 89–96.
[25] J.A. Fraser, V. Biousse, N.J. Newman, The neuro-ophthalmology of mitochondrial dis-
ease, Surv. Ophthalmol. 55 (2010) 299–334.
[26] H.B. Sarnat, J. Marin-Garcia, Pathology of mitochondrial encephalomyopathies, Can.
J. Neurol. Sci. 32 (2005) 152–166.
[27] K.W. Nolte, S. Trepels-Kottek, D. Honnef, J. Weis, C.G. Bien, A. van Baalen, K. Ritter, B.
Czermin, S. Rudnik-Schoneborn, N. Wagner, M. Hausler, Early muscle and brain ul-
trastructural changes in polymerase gamma 1-related encephalomyopathy, Neuro-
pathology 33 (2013) 59–67.
[28] Z. Rifai, S. Welle, C. Kamp, C.A. Thornton, Ragged red ﬁbers in normal aging and in-
ﬂammatory myopathy, Ann. Neurol. 37 (1995) 24–29.
[29] J. Finsterer, H.F. Harbo, J. Baets, C. Van Broeckhoven, S. Di Donato, B. Fontaine, P. De
Jonghe, A. Lossos, T. Lynch, C. Mariotti, L. Schols, A. Spinazzola, Z. Szolnoki, S.J.
Tabrizi, C.M. Tallaksen, M. Zeviani, J.M. Burgunder, T. Gasser, EFNS guidelines on the
molecular diagnosis of mitochondrial disorders, Eur. J. Neurol. 16 (2009) 1255–1264.
[30] L.J. Wong, F. Scaglia, B.H. Graham, W.J. Craigen, Current molecular diagnostic algo-
rithm for mitochondrial disorders, Mol. Genet. Metab. 100 (2010) 111–117.
[31] C.M. Sue, A. Quigley, S. Katsabanis, R. Kapsa, D.S. Crimmins, E. Byrne, J.G. Morris,
Detection of MELAS A3243G point mutation in muscle, blood and hair follicles,
J. Neurol. Sci. 161 (1998) 36–39.
[32] E. Ciafaloni, E. Ricci, S. Shanske, C.T. Moraes, G. Silvestri, M. Hirano, S. Simonetti, C.
Angelini, M.A. Donati, C. Garcia, et al., MELAS: clinical features, biochemistry, and
molecular genetics, Ann. Neurol. 31 (1992) 391–398.
[33] S. Rahman, J. Poulton, D. Marchington, A. Suomalainen, Decrease of 3243 A → G
mtDNA mutation from blood in MELAS syndrome: a longitudinal study, Am. J.
Hum. Genet. 68 (2001) 238–240.
[34] J. Poulton, K. Morten, Noninvasive diagnosis of the MELAS syndrome from blood
DNA, Ann. Neurol. 34 (1993) 116.
[35] P.F. Chinnery, M.A. Johnson, T.M. Wardell, R. Singh-Kler, C. Hayes, D.T. Brown, R.W.
Taylor, L.A. Bindoff, D.M. Turnbull, The epidemiology of pathogenic mitochondrial
DNA mutations, Ann. Neurol. 48 (2000) 188–193.
[36] A.M. Schaefer, R. McFarland, E.L. Blakely, L. He, R.G. Whittaker, R.W. Taylor, P.F.
Chinnery, D.M. Turnbull, Prevalence of mitochondrial DNA disease in adults, Ann.
Neurol. 63 (2008) 35–39.
[37] D. Skladal, J. Halliday, D.R. Thorburn, Minimum birth prevalence of mitochondrial
respiratory chain disorders in children, Brain 126 (2003) 1905–1912.
[38] C.M. Sue, Mitochondrial disease: recognising more than just the tip of the iceberg,
Med. J. Aust. 193 (2010) 195–196.
[39] Y. Kobayashi, M.Y. Momoi, K. Tominaga, T. Momoi, K. Nihei, M. Yanagisawa, Y.
Kagawa, S. Ohta, A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in
MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes), Biochem. Biophys. Res. Commun. 173 (1990) 816–822.
[40] K. Majamaa, J.S. Moilanen, S. Uimonen, A.M. Remes, P.I. Salmela, M. Karppa, K.A.
Majamaa-Voltti, H. Rusanen, M. Sorri, K.J. Peuhkurinen, I.E. Hassinen, Epidemiology
of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and
strokelike episodes: prevalence of the mutation in an adult population, Am. J. Hum.
Genet. 63 (1998) 447–454.
1367C. Liang et al. / Biochimica et Biophysica Acta 1840 (2014) 1360–1367[41] N. Manwaring, M.M. Jones, J.J. Wang, E. Rochtchina, C. Howard, P. Mitchell, C.M. Sue,
Population prevalence of the MELAS A3243G mutation, Mitochondrion 7 (2007)
230–233.
[42] N. Manwaring, J.J. Wang, P. Mitchell, C.M. Sue, Mitochondrial DNA disease preva-
lence: still underrecognized? Ann. Neurol. 64 (2008) 471(author reply 471–472).
[43] H. Vandebona, P. Mitchell, N. Manwaring, K. Grifﬁths, B. Gopinath, J.J. Wang, C.M.
Sue, Prevalence of mitochondrial 1555A→ G mutation in adults of European de-
scent, N. Engl. J. Med. 360 (2009) 642–644.
[44] H.R. Elliott, D.C. Samuels, J.A. Eden, C.L. Relton, P.F. Chinnery, Pathogenic mitochon-
drial DNA mutations are common in the general population, Am. J. Hum. Genet. 83
(2008) 254–260.
[45] C. Liang, C.M. Sue, How to treat:mitochondrial disease, Aust. Dr. 25 (Mar 2011) 27–34.
[46] V. Vasta, J.L. Merritt II, R.P. Saneto, S.H. Hahn, Next-generation sequencing for mito-
chondrial diseases: a wide diagnostic spectrum, Pediatr. Int. 54 (2012) 585–601.
[47] S.E. Calvo, A.G. Compton, S.G. Hershman, S.C. Lim, D.S. Lieber, E.J. Tucker, A.
Laskowski, C. Garone, S. Liu, D.B. Jaffe, J. Christodoulou, J.M. Fletcher, D.L. Bruno, J.
Goldblatt, S. Dimauro, D.R. Thorburn, V.K. Mootha, Molecular diagnosis of infantile
mitochondrial disease with targeted next-generation sequencing, Sci. Transl. Med.
4 (2012) 118ra110.
[48] D.S. Lieber, S.E. Calvo, K. Shanahan, N.G. Slate, S. Liu, S.G. Hershman, N.B. Gold, B.A.
Chapman, D.R. Thorburn, G.T. Berry, J.D. Schmahmann, M.L. Borowsky, D.M.Mueller, K.B. Sims, V.K. Mootha, Targeted exome sequencing of suspected mito-
chondrial disorders, Neurology 80 (2013) 1762–1770.
[49] R.L. Davis, C. Liang, F. Edema-Hildebrand, C. Riley, C.M. Sue, Fibroblast growth
factor-21 is a sensitive biomarker of mitochondrial disease, Neurology 81 (2013)
1819–1826.
[50] A. Suomalainen, J.M. Elo, K.H. Pietilainen, A.H. Hakonen, K. Sevastianova, M. Korpela,
P. Isohanni, S.K. Marjavaara, T. Tyni, S. Kiuru-Enari, H. Pihko, N. Darin, K. Ounap, L.A.
Kluijtmans, A. Paetau, J. Buzkova, L.A. Bindoff, J. Annunen-Rasila, J. Uusimaa, A.
Rissanen, H. Yki-Jarvinen, M. Hirano, M. Tulinius, J. Smeitink, H. Tyynismaa,
FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain de-
ﬁciencies: a diagnostic study, Lancet Neurol. 10 (2011) 806–818.
[51] T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, V. Parameswara, Y. Li, R. Goetz, M.
Mohammadi, V. Esser, J.K. Elmquist, R.D. Gerard, S.C. Burgess, R.E. Hammer, D.J.
Mangelsdorf, S.A. Kliewer, Endocrine regulation of the fasting response by
PPARalpha-mediated induction of Fibroblast Growth Factor 21, Cell Metab. 5
(2007) 415–425.
[52] D.D. Moore, Physiology, Sister Act Sci. 316 (2007) 1436–1438.
[53] H. Tyynismaa, C.J. Carroll, N. Raimundo, S. Ahola-Erkkila, T. Wenz, H. Ruhanen, K.
Guse, A. Hemminki, K.E. Peltola-Mjosund, V. Tulkki, M. Oresic, C.T. Moraes, K.
Pietilainen, I. Hovatta, A. Suomalainen, Mitochondrial myopathy induces a
starvation-like response, Hum. Mol. Genet. 19 (2010) 3948–3958.
